From November 2008, RG was introduced in the Ajou University Hospital (Suwon, Korea). After 517 cases of LG were performed, we prospectively collected patients' demographic data (e.g., sex, age, underlying disease), operating data (e.g., operative time, bleeding, anastomosis type), and post-operative data (e.g., pathology, discharge date, morbidity). Five hundreds seventeen cases of LG were done by one surgeon, and all RG also done by same surgeon. Total 382 cases were enrolled in this study and RG cases were 100. The patients who underwent RG were divided into an initial 20 cases and all subsequent cases.
We defined "underlying disease" as "disease that could affect general anesthesia," and "operating time" as "the time from the initial incision to skin closure." We counted blood loss that suction volume minus irrigation volume. A complication was defined as "an event that delays the normal discharge date".
From November 2008 to March 2011, we reviewed gastric cancer patients who underwent minimally invasive surgeries (RG or LG). Patients whose pre-operative staging was 'T1 or 2' and 'N0 or 1' (American Joint Committee on Cancer [AJCC] 6th edition) were indicated for minimally invasive surgery. RG was selected if patients wanted this type of surgery, regardless of its cost. Combine operation which associated with stomach operation case was included (cholecystectomy or splenectomy) but other combine operation cases were excluded. Open conversion cases or palliative surgery cases were excluded, and there was no conversion to open surgery in robot-assisted cases. We reviewed the operative data and early operative outcomes and analyzed these factors retrospectively.
We defined "underlying disease" as "disease that could affect general anesthesia," and "operating time" as "the time from the initial incision to skin closure." We counted blood loss that suction volume minus irrigation volume. A complication was defined as "an event that delays the normal discharge date".
From November 2008 to March 2011, we reviewed gastric cancer patients who underwent minimally invasive surgeries (RG or LG). Patients whose pre-operative staging was 'T1 or 2' and 'N0 or 1' (American Joint Committee on Cancer [AJCC] 6th edition) were indicated for minimally invasive surgery. RG was selected if patients wanted this type of surgery, regardless of its cost. Combine operation which associated with stomach operation case was included (cholecystectomy or splenectomy) but other combine operation cases were excluded. Open conversion cases or palliative surgery cases were excluded, and there was no conversion to open surgery in robot-assisted cases. We reviewed the operative data and early operative outcomes and analyzed these factors retrospectively.